We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Oxford BioTherapeutics has entered a strategic partnership with WuXi Biologics to develop bispecific antibodies for the treatment of several cancer types, expanding on the existing collaboration between the two.